Drugs / XZP-3287
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05478109 | Aug 2022 → Jan 2023 | — | Xuanzhu Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04951765 | Aug 2021 | — | Xuanzhu Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04951713 | Jul → Sep 2021 | — | Xuanzhu Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05257395 | Mar 2022 → Dec 2025 overdue | female breast carcinoma | Xuanzhu Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05077449 | Nov 2021 → Feb 2024 overdue | breast cancer | Xuanzhu Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XZP-3287 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05257395 ↗ |
| Known as | bireociclib | “Patients received bireociclib, 360 mg, or placebo orally every 12 hours in combination with fulvestrant, 500 mg, intramuscularly (days 1 and 15 of cycle 1, then day 1 of each...” PMID 41854603 ↗ May 2026 |
| Route | Oral | “Drug: XZP-3287, oral, 120 mg once daily for day 1 and day 12” NCT04951713 ↗ |